by Peter Ciszewski | Oct 18, 2017
Douglas Paul, PharmD, PhD discusses the Orphan Drug Act and what the term “Orphan” means in context of the the Rare Disease industry, especially considering that much of the Rare Disease pipeline is for Oncology products. The Orphan Drug Act was first...
by Peter Ciszewski | Oct 17, 2017
Jeremy Levin, Chairman and Chief Executive Officer of Ovid Therapeutics, discusses his company and some important upcoming milestones, including data from Frangile X and Angelman syndrome clinical trials. Ovid Therapeutics is a New York-based, biopharmaceutical...
by Peter Ciszewski | Oct 13, 2017
Jeremy Levin, Chairman and Chief Executive Officer of Ovid Therapeutics, discusses his company’s focus on developing medicines for patients with rare neurological disorders and how neurology compares to where oncology was 20 years ago. Ovid Therapeutics is a New...
by Peter Ciszewski | Oct 12, 2017
David G. Birch, PhD, Chief Scientific and Executive Officer and Director of the Rose-Silverthorne Retinal Degenerations Laboratory, Retina Foundation of the Southwest discusses the current clinical trial for patients suffering from X-linked retinoschisis (XLRS)....
by Peter Ciszewski | Oct 11, 2017
Cory MacDonald, Operations Manager, Choroideremia Research Foundation, discusses the origins of his organization and the various clinical trials for this rare eye disorder. Choroideremia is a condition characterized by progressive vision loss that mainly affects...
